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Cancer is a complex set of diseases involving genetic or epigenetic changes within cells, as
well as interactions between the developing tumour cells and their microenvironment, which leads
to uncontrolled tumour growth, altered differentiation, local invasion and metastasis to distant
sites [1,2]. Molecular changes in oncogenes or tumour suppressor genes promote various cancer
hallmarks, including the continued proliferation, inhibition of differentiation, inhibition of apoptosis,
changes to metabolism, evasion of the immune system and the promotion of invasion/metastasis [3,4].
Although many oncogenes and tumour suppressor gene mutations promote more than one hallmark
of cancer, several mutations are required to generate malignant cancers, a process referred to as
cooperative oncogenesis/tumourigenesis [5,6]. Through decades of research, we have gained much
knowledge on key molecular events and processes involved in the formation of cancer, and much
of this knowledge has stemmed from investigations using model organisms, such as the mouse and
the vinegar fly, Drosophila melanogaster, in addition to in vitro cell line studies. In this Special Issue,
we present a collection of original research papers on various aspects of cancer research utilising human
cell lines [7,8], or in vivo using Drosophila as a model system [9,10], as well as reviews highlighting
the Drosophila model organism in cancer research [11–15]. Drosophila is a particularly useful model
organism for the study of cancer mechanisms, because it has a rapid life cycle and is genetically
manipulatable and since cancer genes and signalling pathways are highly conserved between humans
and Drosophila, and interactions between tumour cells and surrounding normal cells can be readily
examined in Drosophila tissues [6,16–20].
In a research paper pertaining to in vitro models of cancer, Di Giorgio et al. [8] analyse the
transcriptional response to the expression of three key oncogenes (RAS, MYC, and HDAC4) in human
fibroblasts, revealing common signalling pathways that are deregulated by these genes, and suggesting
potential therapeutic avenues for the treatment of cancers driven by these oncogenes. In the second
research paper on this topic, Mayer et al. [7] focus on human pancreatic cancer, where they observe
in tissue sections the infiltration of Th17-like T cells expressing IL21 and IL26, and the expression of
receptors for IL21 and IL26 in the pancreatic epithelial cells. They show in human pancreatic cell lines
that IL21 and IL26 signal through ERK1/2 and STAT, which leads to increased tumour cell growth in
colony forming assays.
In a research paper utilising the Drosophila model, Parniewska and Stocker [9] identify the novel
splicing factor, SF2, which is essential for the survival and hyperproliferation of tissues that upregulate
the target of rapamycin complex 1 (TORC1), a protein kinase involved in cellular growth that is
upregulated in many cancers [21,22]. The identification of SF2 as a key conserved target of TORC1,
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which is required for early tumour growth in Drosophila, provides a potential new approach to develop
anti-cancer therapies for tumours with upregulated TORC1 activity, such as those carrying loss of
function of PTEN (phosphatase and tensin homolog deleted on chromosome ten) or constitutively
active mutations in PI3K (phospho inositol 3 kinase) [23–25]. In a second research paper utilising the
Drosophila model, Hamaratoglu and Atkins [10] undertook an analysis of published transcriptional
data from various Drosophila imaginal disc epithelial cell models of cancer, and found that the
JNK stress response pathway [26,27], and JAK/STAT [28,29], Hippo [30,31] and Notch [32,33] tissue
growth signalling pathways are commonly deregulated. This important meta-analysis has opened-up
new potential avenues of research to examine the cooperative interactions between these signalling
pathways using model organisms, as well as to assess the co-dependency of these conserved pathways
in human cancers.
The reviews in this Special Issue highlight the power of usingDrosophila as an in vivo model system
to study various aspects of cancer research, from its application in the study of the function of specific
genes/pathways in cancer [11,15], to understanding particular cellular processes in cancer [13,14],
and for functional analyses of cancer Omics data [12]. Sechi et al. [15] review the mechanisms of the
Golgi phosphoprotein 3 (GOLPH3) oncogene in cancer, covering research on human cancer samples,
in vitro cell line analyses and Drosophila in vivo analyses. Carmena [11] reviews the involvement of
the Scribble cell polarity module [34] in asymmetric cell division (ACD) of Drosophila neural stem cells
in tumourigenesis, highlighting the importance of correct ACD for appropriate differentiation and
exit from the cell cycle. Casas-Tintó and Portela [14] review the involvement of specialised cellular
extensions, termed cytonemes, in cell–cell communication and in tumourigenesis. Cytonemes have
recently been shown to be highly important in the development of glioblastoma and the associated
neural degeneration that occurs in Drosophila models and also in the human disease [35], and there
is accumulating evidence for their role in tumourigenesis in other cancer types. Newman and
Gregory [13] review the connection between chromosomal aberrations (aneuploidy) and metabolic
changes, highlighting the role of oxidative stress and particularly reactive oxygen species (ROS) in
this process. Finally, Bangi [12] reviews how Drosophila can be utilised to functionally analyse the
vast amount of human cancer Omics data that is currently being generated, in order to validate key
genes/pathways that contribute to cancer, to build new models to interrogate cancer mechanisms,
and to screen for novel cancer therapeutics. Drosophila has already proven its worth in identifying
novel drugs that target particular types of human cancers, such as multiple endocrine neoplasia type
2 (MEN2), colorectal and non-small cell lung cancers [36–42], and undoubtably, the development of
more sophisticated Drosophila models that incorporate additional genetic lesions will enable better
modelling of human cancers and new anti-cancer drug discovery.
This first iteration of this Special Issue on basic and translational models of cooperative oncogenesis
presents only a snapshot of the vast amount of research into cancer currently being conducted
worldwide, yet it highlights the important contribution of the simple multicellular model organism,
Drosophila, to our current understanding of cancer. Undoubtably, further primary research papers and
literature reviews for future iterations of this Special Issue will highlight new cancer genes/pathways
and processes involved in cancer, additional in vivo models of cancer (such as worms, zebra fish,
and mice), and novel approaches for the understanding of cancer mechanisms and for developing new
cancer therapies.
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